People · Operator
Named in public records as an officer, director or promoter · active 2011–2018 · Pharmaceuticals, Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Anaptysbio Inc | — | Pharmaceuticals | Series C | $50.8M | $1.4B | 2011 |
| Qpex Biopharma, Inc. | — | Biotechnology | Series B | $27.4M | $1.1B | 2018 |
Carol N. Gallagher at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Carol N. Gallagher on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| James Topper | 1 | 12 |
| Heath Lukatch | 1 | 10 |
| Tiba Aynechi | 1 | 9 |
| Carol Gallagher | 1 | 6 |
| Robert Hoffman | 1 | 5 |
| James N. Topper | 1 | 5 |
| Kevin Kinsella | 1 | 4 |
| John Schmid | 1 | 4 |
| J Leighton Read | 1 | 2 |
| Hamza N. Suria | 1 | 1 |
| Nick Lydon | 1 | 1 |
| Michael N. Dudley | 1 | 1 |
| Terry N. Gould | 1 | 1 |
| Douglas N. Reed | 1 | 1 |
| Kevin N. Li | 1 | 1 |
| Daniel N. Burgess | 1 | 1 |
| Marco Londei | 1 | 1 |
| Nicholas Lydon | 1 | 1 |
| Hamza Suria | 1 | 1 |
| Hollings Renton | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.